PRESSEPORTAL Presseportal Logo
All Stories
Follow
Subscribe to Stada Arzneimittel

15.02.2021 – 11:20

Stada Arzneimittel

STADA starts European roll-out of Lecigon® Parkinson’s therapy with launches in Germany and Austria

One document

Press release

STADA starts European roll-out of Lecigon® Parkinson’s therapy with launches in Germany and Austria

  • Germany and Austria lead STADA’s European launch of the Lecigon® triple-combination of levodopa, carbidopa and entacapone for treating advanced Parkinson's disease.
  • STADA CEO Peter Goldschmidt: "With Lecigon® we are demonstrating that we are not only the go-to-partner for our Consumer Health and Generics businesses, but also for our strongly growing Specialty Pharmaceuticals segment.“
  • First patients in Austria and Germany are initiating treatment with Lecigon®, which is already being used to treat patients in Nordic countries

Bad Vilbel, 15 February 2021 – STADA is launching Lecigon®, an innovative triple combination product with modern pump technology, in Germany and Austria as the lead markets for the treatment for advanced Parkinson's disease. Lecigon®, to which STADA acquired rights in October 2020, has already been successfully launched in Nordic countries, where patient treatment using the intestinal gel therapy is underway. Sweden acted as the reference member state (RMS) in a European decentralised marketing authorisation procedure in which Austria and Germany participated as concerned member states (CMS), as did Belgium, Denmark, Finland, the Netherlands, Norway, Romania and Slovenia.

In Germany, the prescription-only therapy is being launched with immediate effect by STADAPHARM GmbH, which is responsible for the Specialty Pharmaceuticals business in the STADA Group and brings extensive experience with apomorphine injection and infusion treatments for Parkinson's disease. Launch activities for the novel gel formulation under the Lecigimon® brand name are also underway in Austria through the local STADA Arzneimittel GmbH affiliate that also has extensive experience with apomorphine-based therapies.

The novel gel formulation of the three established Parkinson's active ingredients levodopa, carbidopa and entacapone has a positive effect on the bioavailability of levodopa in the body.[1] [2] The pump can be removed and patients can even bathe, shower or swim ─ if their overall condition permits. This offers patients certain flexibility and the chance to plan and manage their daily life. There are currently about 50,000 people in Germany who suffer from advanced Parkinson's disease and the associated motor fluctuations. Sooner or later, these could potentially be treated with pump therapy.[3] Lecigon® is an excellent example of how STADA is increasingly offering added value for patients and caregivers with differentiated specialty pharmaceuticals. From a company perspective, these products have, due to their differentiation, the potential for sustainable margins over many years.

"We care about people's health and are now also fulfilling this mission with an innovative therapy option for treating Parkinson's disease," emphasises STADA CEO Peter Goldschmidt. "With Lecigon® we are demonstrating that we are not only the go-to-partner for our Consumer Health and Generics businesses, but also for our strongly growing Specialty Pharmaceuticals segment."

STADA’s Head of Germany, Eelco Ockers, and Head of Austria Dr. Martin Spatz add: "We are very pleased with Lecigon® and Lecigimon® to be the first companies in Germany and Austria to offer a novel triple combination product with a modern pump technology that makes a valuable contribution to caring for Parkinson's patients. The gel formulation is a strategically important addition to STADA’s portfolio through which we are intensifying our commitment in the field of neurology and benefiting from our previous experience."

To accompany the launch, in Germany and Austria, STADA is offering a comprehensive package of support services for patients being treated in clinics and at home.

Lecigon® is an infusion therapy administered through a modern, discreet, lightweight and portable pump via a tube into the small intestine. The pump has an intuitive and user-friendly interface and a long battery life. Healthcare professionals can programme multiple flow rates to suit different patient needs. Lecigon® is used to treat advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations do not produce satisfactory treatment results.

About STADA Arzneimittel AG

STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two-pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2019, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. As of December 31, 2019, STADA employed 11,100 people worldwide.

Additional information for journalists:

STADA Arzneimittel AG / Media Relations

Stadastrasse 2-18 / 61118 Bad Vilbel / Germany

Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215

E-Mail: press@stada.de

Or visit us on the Internet at www.stada.com/press

Additional information for capital market participants:

STADA Arzneimittel AG / Investor & Creditor Relations

Stadastrasse 2-18 / 61118 Bad Vilbel / Germany

Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215

E-mail: ir@stada.de

Or visit us on the Internet at www.stada.com/investor-relations

[1] Lecigon® Fachinformation, Stand December 2020

[2] Senek M, et al. Mov Disord. 2017;32(2):283-6

[3] G-BA Dossier Nutzenbewertung „Opicapon“, 2016-09-28_Modul1_Opicapon.pdf (g-ba.de)

STADA information for journalists :

STADA Arzneimittel AG / Media Relations
Stadastrasse 2-18 / 61118 Bad Vilbel / Germany 
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215
E-Mail: press@stada.de 

Or visit us on the Internet at www.stada.com/press

STADA information for capital market participants:

STADA Arzneimittel AG / Investor & Creditor Relations
Stadastrasse 2-18 / 61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-4689 / Fax: +49 (0) 6101 603-215
E-mail: ir@stada.de 

Or visit us on the Internet at www.stada.com/investor-relations

Uriach Media Contact

Belén Badia, Director of Communications

belen.badia@uriach.com

+34 938 630 13

+34 619 688 199

Oriol Giménez, Communications Manager

oriol.gimenez@uriach.com

+34 938 630 187

+34 635 565 045